BamSEC and AlphaSense Join Forces
Learn More

Cephalon Inc

Formerly NASDAQ: CEPH
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1
from SC14D9C 4 pages Cephalon’s Board of Directors Rejects Valeant Pharmaceuticals’ Unsolicited Proposal · Determines That Proposal Fails to Recognize Full Value of Cephalon Shares
12/34/56
EX-1
from DEFA14A 4 pages Cephalon’s Board of Directors Rejects Valeant Pharmaceuticals’ Unsolicited Proposal · Determines That Proposal Fails to Recognize Full Value of Cephalon Shares
12/34/56
EX-1
from SC14D9C 6 pages News Release Cephalon Confirms Receipt of Unsolicited Proposal From Valeant Pharmaceuticals 03/29/2011
12/34/56
EX-1
from DEFA14A 6 pages News Release Cephalon Confirms Receipt of Unsolicited Proposal From Valeant Pharmaceuticals 03/29/2011
12/34/56
EX-1.2
from 8-K 44 pages 5,000,000 Shares Cephalon, Inc. Common Stock ($0.01 Par Value) Underwriting Agreement
12/34/56
EX-1.1
from 8-K 47 pages $435,000,000 Cephalon, Inc. 2.50% Convertible Senior Subordinated Notes Due May 1, 2014 Underwriting Agreement
12/34/56
EX-1
from SC 13G/A 1 page Exhibit 1 Power of Attorney for Certain Filings Under the Securities Exchange Act of 1934
12/34/56
EX-1
from SC 13G/A 1 page Exhibit 1 Power of Attorney for Certain Filings Under the Securities Exchange Act of 1934
12/34/56
EX-1.1
from 8-K 33 pages $800,000,000 Cephalon, Inc. 2.00% Convertible Senior Subordinated Notes Due June 1, 2015 Underwriting Agreement
12/34/56
EX-1
from 8-A12G/A ~50 pages Cephalon, Inc. and Stocktrans, Inc., as Rights Agent Second Amended and Restated Rights Agreement Dated as of October 27, 2003
12/34/56
EX-1
from 8-A12G 1 page Rights Agreement
12/34/56